Hims & Hers (NYSE: HIMS ) is up 260% in the last year, and I'm not surprised at all. This is a stock that is reimagining healthcare and making it more affordable and convenient for its users. This is a high-risk/high-reward opportunity, which is exactly what I look for in my YOLO portfolio. Joint the Pragmatic Investor today to get insight into stocks with high return potential. You will also get: - Weekly Macro newsletter - Access to the End of The World and YOLO portfolios - Trade Ideas - Weekly Video ...

Key Takeaways Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage. The change would be a boon for Hims & Hers, which makes copycat weight-loss drugs, and has benefited from the limited availability of some obesity medicines. With Monday's gains, Hims & Hers shares have more than doubled in value since the start of the year. Hims & Hers Health (HIMS) shares surg ...

Shares of Hims & Hers Health Inc (NYSE:HIMS) are popping 10% higher to trade at $20.50 this morning, running higher off good news from the Food and Drug Administration (FDA). The FDA announced it will allow compounding pharmacies to create and sell their own version of Eli Lilly's (LLY) weight-loss drug Mounjaro. In response, HIMS is enjoying a healthy bull gap, pacing toward its highest close since July, and has now broken above the resistant $20 level. The stock sports a 230% year-over-year gain, but stil ...

Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright? Hims & Hers (HIMS 4.71%) stock has been on a roller coaster about the availability of GLP-1s to its customers. However, the focus on one treatment may miss the company's strategy. In this video, Travis Hoium shows why Hims & Hers will be fine with or without GLP-1s. *Stock prices used were end-of-day prices of Oct. 7, 2024. The video was published on Oct. 8, 2024. ...

Look beyond the stock price at the business when shares are volatile. When the stock market is volatile and share prices tumble, opportunities arise to search for great businesses with stocks temporarily trading at bargain levels. When this happens, investors with a multiyear buy-and-hold strategy can shrewdly add such stocks to their portfolio while others sit on the sidelines. It's true that just because a stock is trading lower doesn't necessarily mean it has become a better buy. Sometimes, stocks trade ...

Consistently investing even moderate sums can grow your portfolio with time. Bull and bear markets come and go, and along with them come short-term investment opportunities. However, investors with a long-term buy-and-hold perspective can find opportunities in any market environment. And those opportunities don't always require a lot of available cash to tap into. Even with a more modest stash of cash -- say $500 -- to invest, you can find plenty of companies to put some or all of that amount into to benefi ...

Hims & Hers Health, Inc. (HIMS) shares rallied 10.1% in the last trading session to close at $19.44. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 29.4% gain over the past four weeks. Hims & Hers Health scored a strong price increase driven by investors' optimism following the news of the company joining the S&P SmallCap 600. Per S&P Dow Jones' – a division of S&P Global press release, Hims & Hers will repl ...

The healthcare sector is usually regarded as one of the safest and most stable spaces in the market, which becomes especially important and attractive during volatile periods such as today in the S&P 500 index. However, there is still a preference for the technology sector, and this preference is now being diversified away from the semiconductor industry and into other niches. Hims & Hers Health Today HIMS Hims & Hers Health $19.44 +1.78 (+10.08%) 52-Week Range $5.65 ▼ $25.74 Price Target $19.86 Add to Watc ...

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 9, 2024S&P SmallCap 600 Ad ...

Hims & Hers may not be hurt by GLP-1 news the way investors think. Shares of Hims & Hers (HIMS -9.60%) fell as much as 15% on Thursday after news that Eli Lilly's (LLY -0.62%) GLP-1 drug was taken off the shortage list by the FDA. This could impact Hims & Hers' GLP-1 strategy, but it may not have the impact you think. In this video, Travis Hoium covers the day's news and why this isn't a big deal for investors. *Stock prices used were end-of-day prices of Oct. 3, 2024. The video was published on Oct. 3, 202 ...